More Company News

Allergy Therapeutics

Data at WAO-BSACI
25 Apr 2022Read More

Allergy Therapeutics

H122 interim results
03 Mar 2022Read More

Allergy Therapeutics

New data at AAAAI 2022 meeting
01 Mar 2022Read More

Allergy Therapeutics

New credit facility secured
02 Feb 2022Read More

Allergy Therapeutics

FDA clearance of IND application for VLP Peanut
26 Jan 2022Read More

Allergy Therapeutics

H122 trading update & notice of results
13 Jan 2022Read More

Allergy Therapeutics

Positive top line results from G309 exploratory field trial
25 Oct 2021Read More

Allergy Therapeutics

Preliminary FY21 results
23 Sep 2021Read More

Allergy Therapeutics

Secondary endpoints from VLP Peanut 001
13 Sep 2021Read More

Allergy Therapeutics

Successful primary outcome of VLP Peanut 001
03 Aug 2021Read More

1 2 3
Return to Allergy Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).